{"id":22779,"date":"2023-01-26T09:38:11","date_gmt":"2023-01-26T08:38:11","guid":{"rendered":"https:\/\/idibell.cat\/?p=22779"},"modified":"2023-01-26T09:38:32","modified_gmt":"2023-01-26T08:38:32","slug":"el-trasplantament-allogenic-dun-donant-de-registre-compatible-pot-tenir-millors-resultats-que-el-dun-familiar-que-tingui-menys-compatibilitat","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2023\/01\/el-trasplantament-allogenic-dun-donant-de-registre-compatible-pot-tenir-millors-resultats-que-el-dun-familiar-que-tingui-menys-compatibilitat\/","title":{"rendered":"El trasplantament al\u00b7log\u00e8nic d\u2019un donant de registre compatible pot tenir millors resultats que el d\u2019un familiar que tingui menys compatibilitat"},"content":{"rendered":"<p>Davant del tractament d\u2019un limfoma que requereixi un trasplantament al\u00b7log\u00e8nic es recomana que el donant provingui d\u2019un registre amb alta compatibilitat, abans que d\u2019un donant amb relaci\u00f3 familiar per\u00f2 que tingui una compatibilitat m\u00e9s baixa (haploid\u00e8ntic). Aquesta \u00e9s la principal conclusi\u00f3 que s\u2019extreu de l\u2019estudi publicat a la revista \u2018<em><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36577482\/\">Transplantation and Cellular Therapy<\/a><\/em>\u2019 i que ha estat realitzat per un grup d\u2019investigadors de l\u2019Institut Catal\u00e0 d\u2019Oncologia i l\u2019IDIBELL, amb la col\u00b7laboraci\u00f3 de <a href=\"https:\/\/www.ebmt.org\/\">l\u2019European Bone Marrow Trasplantation Society<\/a> (EBMT) i el <a href=\"https:\/\/cibmtr.org\/\">Center for International Blood and Marrow Trasplant Research<\/a> (CIBMTR). L\u2019estudi ha estat encap\u00e7alat pel coordinador de la Unitat de Trasplantaments Hemopo\u00e8tics i Ter\u00e0pia Cel\u00b7lular de l\u2019ICO l\u2019Hospitalet, Alberto Mussetti, amb la participaci\u00f3 de la cap del Servei d\u2019Hematologia Cl\u00ednica de l\u2019ICO l\u2019Hospitalet, Anna Sureda, ambd\u00f3s membres del <a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/tumors-hematopoeticos-i-linfoides\/\">grup de Tumors Hematopo\u00e8tics i Limfoides<\/a> de l\u2019IDIBELL.<\/p>\n<p>Fins a dia d\u2019avui, i segons les recomanacions m\u00e8diques internacionals, quan es busca un donant per a realitzar un trasplantament de moll d\u2019os, la primera opci\u00f3 sempre \u00e9s la d\u2019un donant familiar amb alta compatibilitat (100%). La segona opci\u00f3 \u00e9s buscar un donant d\u2019alta compatibilitat de registre i, com a \u00faltima opci\u00f3, un familiar haploid\u00e8ntic (de compatibilitat entre el 50-70%). Tot i aix\u00ed, alguns centres, si no hi ha un donant familiar d\u2019alta compatibilitat passen directament a un donant familiar haploid\u00e8ntic. Aix\u00f2 sobretot passa quan s\u2019utilitza ciclofosfamida per tal de reduir la malaltia de l&#8217;empelt contra l&#8217;hoste despr\u00e9s del trasplantament. Tanmateix, els resultats d\u2019aquest estudi demostren que, davant d\u2019un trasplantament, cal prioritzar el donant de registre d\u2019alta compatibilitat que el familiar haploid\u00e8ntic ja que milloren els resultats posteriors.<\/p>\n<p>&nbsp;<\/p>\n<h3>Com s\u2019ha realitzat aquest estudi?<\/h3>\n<p>Per tal de poder realitzar aquest estudi s\u2019han utilitzat les dades de 2.140 pacients provinents, principalment, de dues bases de dades internacionals, els abans mencionats EBMT i CIBMTR. Aquests pacients, tots ells majors de 18 anys, havien rebut entre el 2010 i el 2019 un trasplantament de c\u00e8l\u00b7lules hematopo\u00e8tiques, tant de donants familiars haploid\u00e8ntics com de donants de registre compatible per\u00f2 amb una concordan\u00e7a de compatibilitat elevada, i tractament amb ciclofosfamida posterior.<\/p>\n<p>Un cop analitzades les dades s\u2019ha pogut veure que despr\u00e9s de realitzar el trasplantament i rebre tractament farmacol\u00f2gic amb ciclosfosfamida, els pacients que havien rebut el trasplantament de donant de registre per\u00f2 amb alta comptabilitat tenien millors resultats que els que l\u2019havien rebut d\u2019un donant familiar haploid\u00e8ntic. Aix\u00ed doncs es pot observar una major toxicitat entre els donants familiars haploid\u00e8ntics, el que pot acabar afectant a la seva superviv\u00e8ncia. Per altra banda no es van observar difer\u00e8ncies significatives pel que fa a les recaigudes de la malaltia i la regeneraci\u00f3 dels neutr\u00f2fils un cop realitzat el trasplantament.<\/p>\n<p>Segons Alberto Mussetti, aquests resultats demostren que \u201cdavant un trasplantament al\u00b7log\u00e8nic, i posterior tractament amb ciclofosfamida, cal buscar el donant m\u00e9s compatible tal i com marquen les normes internacionals ja que aix\u00f2 acaba revertint directament en el pacient\u201d.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un estudi liderat per l\u2019Institut Catal\u00e0 d\u2019Oncologia i l\u2019IDIBELL, publicat a la revista cient\u00edfica \u2018Transplantation and Cellular Therapy\u2019, conclou que, sempre que sigui possible, \u00e9s millor que el pacient rebi el trasplantament d\u2019un donant de registre d\u2019alta compatibilitat que d\u2019un donant haploid\u00e8ntic amb vincle familiar, per\u00f2 de menor compatibilitat.<\/p>\n","protected":false},"author":8,"featured_media":22780,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-22779","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar"],"publishpress_future_action":{"enabled":false,"date":"2024-09-14 16:49:11","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22779"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=22779"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22779\/revisions"}],"predecessor-version":[{"id":22781,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22779\/revisions\/22781"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22780"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=22779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=22779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=22779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}